Background Osteopontin (OPN) mRNA is highly expressed in atherosclerotic plaques and plasma OPN levels are high in patients with coronary artery disease and in those with restenosis. OPN-overexpressing transgenic mice show markedly increased neointimal formation after arterial injury.
n 1993, osteopontin (OPN), which is a phosphoprotein originally found in bone, was reported to be a novel component of atherosclerotic plaques. 1 Subsequent studies showed high levels of OPN mRNA and proteins in human atherosclerotic plaques of the aorta and carotid and coronary arteries, most profoundly associated with calcification. [2] [3] [4] We also reported plasma OPN levels to be higher in patients with coronary artery disease (CAD) than in those without CAD, and to be associated with the severity of CAD. 5 These observations suggest that OPN plays an important role in the development of atherosclerosis and CAD.
In vitro, OPN promotes the migration and proliferation of vascular smooth muscle cells. [6] [7] [8] Increased OPN mRNA expression is found in neointimal smooth muscle cells after arterial injury in animal models. 1,9,10 OPN-overexpressing transgenic mice demonstrate markedly increased neointimal formation after arterial injury. 11 Moreover, anti-OPN antibody treatment inhibits neointimal formation after injury in rat carotid arteries. 12 In humans, high levels of OPN mRNA and proteins in coronary atherectomy specimens from restenotic lesions have been reported. 13 We recently reported high plasma levels of OPN in patients with restenosis after percutaneous coronary intervention (PCI). 14 These findings suggest that OPN also plays a role in the pathological processes associated with neointimal proliferation, such as restenosis after PCI. The present study was designed to determine the prognostic value of the preprocedural plasma OPN level on restenosis and clinical outcome in patients undergoing PCI.
Methods

Study Patients
We measured the preprocedural plasma OPN level in 130 consecutive patients with CAD (mean age 65±9 years; 104 men (80%)) who underwent PCI for native coronary stenotic lesions at the National Defense Medical College Hospital. Any patients with acute myocardial infarction, those who underwent drug-eluting stent implantation, those with a history of coronary artery bypass surgery, or those with cardiomyopathies or valvular heart disease were excluded; however, 9 patients with unstable angina at rest were included. Our study was approved by the institutional ethics committee. After written informed consent was given by all the study patients, overnight-fasting blood samples were taken on the morning of the day that PCI was scheduled.
Plasma OPN Measurement
Blood samples were collected in EDTA-containing tubes and were centrifuged at 2,000 g for 15 min at 4°C. The plasma was stored at -80°C until analyzed. Plasma OPN levels were measured by enzyme-linked immunosorbent assay using a commercially available kit (Human OPN assay kit, IBL, Fujioka, Japan), which is based on the method reported by Kon et al 15 and measures the total concentrations of phosphorylated and nonphosphorylated forms of OPN in plasma. All OPN measurements were performed by R. Ohmori. Serum lipid levels were measured by standard laboratory methods. Plasma levels of high-sensitivity C-reactive protein (hsCRP) were also measured using a BNII nephelometer (Dade Behring, Tokyo, Japan).
Coronary Angiography and Follow-up
Coronary angiograms were recorded using the Judkins technique and the cineangiogram system (Toshiba, Tokyo, Japan). Minimal luminal diameter, reference diameter, and percent diameter stenosis were assessed using computerized quantitative angiography. CAD was defined as the presence of at least 1 coronary artery with >50% luminal diameter stenosis. Of the 130 patients undergoing PCI, 89 (68%) had bare metal stent implantation, because of either a coronary dissection or a suboptimal result (>30% residual stenosis) after angioplasty. Balloon catheters and stents were selected by the interventionists. Although all patients were instructed to undergo 6-month follow-up angiography, only 91 (70%) patients underwent repeat angiography at 7±3 months after PCI. Angiographic restenosis was defined as >50% luminal diameter stenosis in the segment treated by PCI. All the 130 study patients were followed for up to 3 years (29±19 months) for major adverse cardiovascular events (MACE) (death, non-fatal myocardial infarction, hospitalization for rest unstable angina, or stroke), which was evaluated by reviewing their medical records supplemented by telephone interview of the patients and their families.
Statistical Analysis
Differences between 2 groups were evaluated by unpaired t-test for parametric variables, by Mann-Whitney U test for nonparametric variables, and by chi-square test for categorical variables. The correlation between OPN and hsCRP levels was evaluated by Spearman's rank correlation test. A forward stepwise multiple logistic regression analysis was used to elucidate any association between plasma OPN or hsCRP levels and restenosis. The eventfree survival in patients with and without OPN >500 ng/ml was analyzed using the Kaplan-Meier method and was compared by log-rank test. This cutoff level of OPN was determined by receiver-operating characteristic curve analysis. Multivariate Cox proportional hazards regression analysis was used to identify independent predictors for MACE. A P-value <0.05 was considered to be statistically significant. Results are presented as the mean value ± SD or the median value. 
Results
Of the 91 patients who underwent repeat angiography at 7±3 months after PCI, 40 (44%) were found to have angiographic restenosis and of them, 13 were rehospitalized for rest unstable angina. Compared with the 51 patients without restenosis, the 40 with restenosis had a lower rate of current smoking (10% vs 29%, P<0.05) ( Table 1) . There was no difference in the preprocedural plasma OPN (492±200 vs 482± 224 ng/ml) and hsCRP (median 0.78 vs 0.70 mg/L) levels between patients with and without restenosis (P= NS). Regarding the angiographic data at PCI (Table 2) , the reference diameter was smaller in patients with restenosis than in those without it (P<0.05), but the prevalence of stent implantation and the medications after PCI were similar in the 2 groups. In the multiple logistic regression analysis, current smoking and the reference diameter were independent predictors for angiographic restenosis, but plasma OPN or hsCRP level was not ( Table 3) .
During the 3-year follow-up, MACE occurred in 21 (16%) of 130 patients (1 sudden death, 18 unstable angina, 2 stroke). Of the 18 patients with unstable angina, 13 were found to have restenosis. Compared with the 109 patients without MACE, the 21 affected patients were older (71±6 vs 64±9 years, P<0.005) and tended to have a higher rate of hypertension ( Table 4) . The percentage of patients with a history of myocardial infarction did not differ between the 2 groups. Regarding the angiographic data at PCI ( the number of coronary vessels with >50% stenosis was greater in patients with MACE than in those without it (P<0.05), but the prevalence of stent implantation and the medications after PCI did not differ between the 2 groups. Notably, patients with MACE had higher levels of OPN (586±230 vs 438±195 ng/ml, P<0.005) and hsCRP (1.30 vs 0.70 mg/L, P<0.002) than those without MACE ( Table 4) . Even compared with 60 age-and gender-matched patients without MACE (age 71±5 years; 46 men (77%)), the 21 patients with MACE had higher OPN (586±230 vs 449±194 ng/ml) and hsCRP (1.30 vs 0.70 mg/L) levels (P<0.01). Patients with MACE more often had an OPN level >500 ng/ml (62% vs 35%) and an hsCRP level >1.0 mg/L (71% vs 36%) than those without MACE (P<0.05). Kaplan-Meier analysis demonstrated a lower event-free survival rate for patients with OPN level >500 ng/ml than for those without it (P<0.05) (Fig 1) .
To clarify the interaction between the OPN and hsCRP levels, the 130 study patients were divided into 4 groups according to the presence of high OPN (>500 ng/ml) and/or high hsCRP (>1.0 mg/L) level: 47 with neither, 29 with high OPN alone, 32 with high hsCRP alone, and 22 with combined high OPN and hsCRP levels. A stepwise increase in the incidence of MACE was found according to the presence of high OPN and/or high hsCRP: 6% in the group with neither, 10% with high OPN alone, 16% with high hsCRP alone, and 45% with combined high OPN and hsCRP levels. The incidence of MACE was highest in the group with combined high OPN and hsCRP levels (P<0.025). OPN levels did not significantly correlate with hsCRP levels. In the multivariate Cox proportional hazard analysis, both the OPN and hsCRP level were independent predictors for MACE. The hazard ratios for MACE were 1.3 (95% confidence interval (CI) 1.1-1.5) for a 100 ng/ml increase in OPN levels and 3.6 (95%CI 1.4-9.3) for hsCRP >1.0 mg/L (P<0.02) ( Table 6 ).
Discussion
The present study investigated the prognostic value of the preprocedural plasma OPN level in 130 patients undergoing PCI. Plasma OPN and hsCRP levels did not differ between patients with and without restenosis. During the 3-year follow-up, MACE occurred in 21 patients and compared with the patients without MACE, those 21 had higher OPN and hsCRP levels. In the multivariate analysis, OPN and hsCRP levels were both found to be independent predictors for MACE, but they were not predictors for restenosis.
Restenosis remains an important clinical problem after PCI. Restenosis after angioplasty is caused by both negative arterial remodeling and neointimal proliferation, whereas in-stent restenosis is caused mainly by neointimal proliferation. 16, 17 In vitro, OPN promotes the migration and proliferation of smooth muscle cells. [6] [7] [8] Increased OPN mRNA expression in neointimal smooth muscle cells in animal models has been reported 1,9,10 and OPN-transgenic mice show marked neointimal formation. 11 Anti-OPN antibody treatment inhibits neointimal formation in rat arteries. 12 In humans, high levels of OPN mRNA and protein have been shown in restenotic lesions. 13 Panda et al reported that the plasma OPN levels in 13 patients undergoing coronary atherectomy were elevated after atherectomy and were still high for at least 4 weeks. 6 We previously reported that high plasma levels of OPN were associated with the presence of restenosis in patients with a history of PCI. 14 Those findings suggested that OPN plays a role in the develop- ment of restenosis associated with neointimal proliferation, so we expected that the preprocedural plasma OPN level would be a predictor for restenosis, but in the present study, it did not differ between patients with and without restenosis and was not an independent predictor for restenosis. In the present study, neither the OPN nor the hsCRP level was high in patients with restenosis, nor were they independent predictors for restenosis. High preprocedural hsCRP levels related to the development of restenosis have been reported in a few studies, 18, 19 but many other studies have not found such a relationship, [20] [21] [22] [23] instead showing that hsCRP levels predict adverse cardiovascular events, but not restenosis, in patients undergoing PCI. [18] [19] [20] [21] [22] [23] Our study is the first to demonstrate that the preprocedural levels of hsCRP and OPN were high in patients who suffered postprocedural MACE and are independent predictors for MACE in patients undergoing PCI.
We previously reported that the plasma OPN level was high in patients with stable CAD and was associated with the severity of CAD; 5 however, it was recently reported that plasma OPN levels are higher in patients with unstable angina than in those with stable CAD. 24, 25 Moreover, the concentration of OPN in carotid endarterectomy specimens from symptomatic patients with carotid stenosis was 4-fold higher than in those from asymptomatic patients with carotid stenosis. 26 OPN may play a role in plaque instability, and high plasma levels of OPN may reflect plaque instability or may be involved in plaque destabilization. Although plasma OPN levels are reportedly high in patients with heart failure, 27 none of the present patients had heart failure. In our study, high plasma levels of OPN were found to be related to further cardiovascular events in patients undergoing PCI, which is consistent with the results of a recent study by Minoretti et al 28 who investigated plasma OPN levels in patients with stable CAD and reported that OPN levels are independent predictors for adverse cardiovascular events. Therefore, in patients undergoing PCI, as well as in those with stable CAD, high plasma levels of OPN indicate a high risk for further cardiovascular events.
Study Limitations
One of the major limitations of the present study is the relatively small number of patients. Of the 130 consecutive patients undergoing PCI, 89 (68%) underwent stent implantation and only 91 (70%) underwent 6-month follow-up angiography. A further study with follow-up angiography in a larger number of patients with stent implantation is needed to confirm the predictive value of the preprocedural plasma OPN level for cardiovascular events and restenosis. Moreover, only 9 patients (7%) had rest unstable angina before PCI. Further study is also needed to elucidate the predictive value of plasma OPN level in patients with acute coronary syndromes.
Conclusion
Preprocedural plasma levels of OPN and hsCRP were found to be independent predictors for further cardiovascular events in patients undergoing PCI. However, our study could not show that the preprocedural OPN level was a predictor for angiographic restenosis.
